A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02548585

Recruitment Status : Completed

First Posted : September 14, 2015

Last Update Posted : July 13, 2017

Sponsor:

Information provided by (Responsible Party):

MedImmune LLC

Study Description

Brief Summary:

A Phase 1/2, multiple dose study with 6 cohorts of ascending doses designed to evaluate the efficacy, safety and pharmacokinetics (PK) of MEDI0382 in patients with Type 2 Diabetes Mellitus (T2DM).

Condition or disease	Intervention/treatment	Phase
Type 2 Diabetes Mellitus	Drug: MEDI0382 Drug: Placebo	Phase 1 Phase 2

Detailed Description:

This is a randomized, double-blind, placebo controlled study designed to evaluate the efficacy, safety, and PK of MEDI0382 administered as multiple daily SC doses to subjects with T2DM. Approximately one hundred and seven subjects will be enrolled across 6 cohorts. In cohorts 1-3 the subjects will be randomized to MEDI0382 or placebo (3:1). In Cohort 4, subjects will be randomized 1:1. In cohort 5 and 6 subjects will be randomized to MEDI0382 or placebo (3:1).

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	113 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double (Participant, Investigator)
Primary Purpose:	Treatment
Official Title:	A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Overweight and Obese Subjects With a History of Type 2 Diabetes Mellitus
Actual Study Start Date :	December 9, 2015
Actual Primary Completion Date :	February 24, 2017
Actual Study Completion Date :	February 24, 2017

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Type 2 diabetes

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: MEDI0382 MEDI0382 administered subcutaneously	Drug: MEDI0382 MEDI0382 administered subcutaneously
Placebo Comparator: Placebo Placebo administered subcutaneously	Drug: Placebo Placebo administered subcutaneously

Outcome Measures

Primary Outcome Measures :

Percent change from baseline in MMT glucose AUC (up to 240 minutes post MMT) to end of treatment (Cohort 4 only) [ Time Frame: 42 days post dosing ]
Percent change from baseline in MMT glucose AUC (up to 240 minutes post MMT) to end of treatment (Cohort 4 only)
Change from baseline in body weight in kg to end of treatment (Cohort 4 only) [ Time Frame: 42 days post dosing ]
Change from baseline in body weight in kg to end of treatment (Cohort 4 only)

Secondary Outcome Measures :

Change from baseline in HbA1c to end of treatment [ Time Frame: 42 days post dosing ]
Change from baseline in HbA1c to end of treatment
Change from baseline in fructosamine to end of treatment [ Time Frame: 42 days post dosing ]
Change from baseline in fructosamine to end of treatment
Number of subjects with adverse events as a measure of safety and tolerability of MEDI0382 [ Time Frame: Cohort 1: 8 days post dosing Cohort 2: 12 days post dosing Cohort 3: 16 days post dosing Cohort 4: 42 days post dosing Cohort 5: 22 days post dosing Cohort 6: 17 days post dosing ]
Treatment emergent adverse events (TEAEs) and serious adverse events (TESAEs)
Number of subjects with adverse events as a measure of safety and tolerability of MEDI0382 [ Time Frame: Cohort 1: 8 days post dosing Cohort 2: 12 days post dosing Cohort 3: 16 days post dosing Cohort 4: 42 days post dosing Cohort 5: 22 days post dosing Cohort 6: 17 days post dosing ]
Clinical laboratory assessments (serum chemistry, hematology, urinalysis)
Number of subjects with adverse events as a measure of safety and tolerability of MEDI0382 [ Time Frame: Cohort 1: 8 days post dosing Cohort 2: 12 days post dosing Cohort 3: 16 days post dosing Cohort 4: 42 days post dosing Cohort 5: 22 days post dosing Cohort 6: 17 days post dosing ]
12 lead electrocardiogram including RR, PR, QRS, QT and QTc intervals
Number of subjects with adverse events as a measure of safety and tolerability of MEDI0382 [ Time Frame: Cohort 1: 8 days post dosing Cohort 2: 12 days post dosing Cohort 3: 16 days post dosing Cohort 4: 42 days post dosing Cohort 5: 22 days post dosing Cohort 6: 17 days post dosing ]
Vital signs (systolic and diastolic blood pressure, pulse rate, temperature, and respiratory rate)
Number of subjects with adverse events as a measure of safety and tolerability of MEDI0382 [ Time Frame: Cohort 1: 8 days post dosing Cohort 2: 12 days post dosing Cohort 3: 16 days post dosing Cohort 4: 42 days post dosing Cohort 5: 22 days post dosing Cohort 6: 17 days post dosing ]
Physical examination
Pharmacokinetics of MEDI0382, maximum plasma concentration (Cmax) [ Time Frame: Cohort 1: 8 days post dosing Cohort 2: 12 days post dosing Cohort 3: 16 days post dosing Cohort 4: 42 days post dosing Cohort 5: 22 days post dosing Cohort 6: 17 days post dosing ]
Pharmacokinetics of MEDI0382, maximum plasma concentration (Cmax)
Pharmacokinetics of MEDI0382, time to maximum observed plasma drug concentration (Tmax) [ Time Frame: Cohort 1: 8 days post dosing Cohort 2: 12 days post dosing Cohort 3: 16 days post dosing Cohort 4: 42 days post dosing Cohort 5: 22 days post dosing Cohort 6: 17 days post dosing ]
Pharmacokinetics of MEDI0382, time to maximum observed plasma drug concentration (Tmax)
Pharmacokinetics of MEDI0382, area under the curve concentration (AUC) [ Time Frame: Cohort 1: 8 days post dosing Cohort 2: 12 days post dosing Cohort 3: 16 days post dosing Cohort 4: 42 days post dosing Cohort 5: 22 days post dosing Cohort 6: 17 days post dosing ]
Pharmacokinetics of MEDI0382, area under the curve concentration (AUC)
Proportion of subjects with ADA to MEDI0382 [ Time Frame: Cohort 1: 8 days post dosing Cohort 2: 12 days post dosing Cohort 3: 16 days post dosing Cohort 4: 42 days post dosing Cohort 5: 22 days post dosing Cohort 6: 17 days post dosing ]
Proportion of subjects with ADA to MEDI0382
Number of subjects with any suicidal behavior assessed by using Columbia-Suicide Severity Rating Scale (C-SSRS) score during treatment period (Cohort 4) [ Time Frame: 42 days post dosing ]
Number of subjects with any suicidal behavior assessed by using Columbia-Suicide Severity Rating Scale (C-SSRS) score during treatment period (Cohort 4)
Number of subjects who reported any suicidal ideation assessed by using Columbia-Suicide Severity Rating Scale (C-SSRS) score during treatment period (Cohort 4) [ Time Frame: 42 days post dosing ]
Number of subjects who reported any suicidal ideation assessed by using Columbia-Suicide Severity Rating Scale (C-SSRS) score during treatment period (Cohort 4)
Change from baseline in body weight in kg to end of treatment [ Time Frame: Cohort 1: 8 days post dosing Cohort 2: 12 days post dosing Cohort 3: 16 days post dosing Cohort 4: 42 days post dosing Cohort 5: 22 days post dosing Cohort 6: 17 days post dosing ]
Change from baseline in body weight in kg to end of treatment
Percent change from baseline in MMT glucose AUC (up to 240 minutes post-MMT) to end of treatment [ Time Frame: Cohort 1: 8 days post dosing Cohort 2: 12 days post dosing Cohort 3: 16 days post dosing Cohort 4: 42 days post dosing Cohort 5: 22 days post dosing Cohort 6: 17 days post dosing ]
Percent change from baseline in MMT glucose AUC (up to 240 minutes post-MMT) to end of treatment

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosis of T2DM, ages 18-65
Must provide written informed consent
BMI >27 and <40 kg/m2, inclusive
Venous access suitable for multiple cannulations
Vital signs within normal specified ranges
Females must be non-lactating and non-childbearing potential
Males must practice 2 effective contraceptive measures if sexually active

Exclusion Criteria:

Any concurrent condition that in the opinion of the investigator would interfere with the evaluation of the investigational product
History or presence of gastrointestinal, renal, or hepatic disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
History of cancer within the last 10 years, with the exception of non-melanoma skin cancer
Any clinically important illness (except for T2DM), medical/surgical procedure, or trauma within 4 weeks prior to dosing
Fasting glucose ≥ 200 mg/dL
Positive Hepatitis B, Hepatitis C or HIV test or use of antiretroviral medications at screening.
Concurrent or previous use of a GLP-1 receptor agonist
Current or previous use of systemic corticosteroids within the past 28 days prior to screening
Use of any medicinal products or herbal preparations licensed for control of body weight or appetite is prohibited.
Known or suspected history of alcohol or drug abuse within the past 3 years.
Positive drug screen

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02548585

Locations


Germany
Research Site
Berlin, Germany, 10117
Research Site
Erfurt, Germany, 99084
Research Site
Kiel, Germany, 24105
Research Site
Leipzig, Germany, 04103
Research Site
Lübeck, Germany, 23538
Research Site
Magdeburg, Germany, 39120
Research Site
Mainz, Germany, 55116
Research Site
Mannheim, Germany, 68167
Research Site
München, Germany, 81241
Research Site
Neu-Ulm, Germany, 89231
Research Site
Neuss, Germany, 41460

Sponsors and Collaborators

MedImmune LLC

Investigators


Principal Investigator:	Michael Stumvoll	Universitätsklinikum Leipzig

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018 Jun 30;391(10140):2607-2618. doi: 10.1016/S0140-6736(18)30726-8. Epub 2018 Jun 23.


Responsible Party:	MedImmune LLC
ClinicalTrials.gov Identifier:	NCT02548585 History of Changes
Other Study ID Numbers:	D5670C00002
First Posted:	September 14, 2015 Key Record Dates
Last Update Posted:	July 13, 2017
Last Verified:	July 2017


Studies a U.S. FDA-regulated Drug Product:		No
Studies a U.S. FDA-regulated Device Product:		No

Keywords provided by MedImmune LLC:


MEDI0382, diabetes

Additional relevant MeSH terms:


Diabetes Mellitus Diabetes Mellitus, Type 2 Overweight Glucose Metabolism Disorders	Metabolic Diseases Endocrine System Diseases Body Weight Signs and Symptoms

To Top